Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

DLTX Stock Over 11% Down So Far On Wednesday

Loading stream...

(VIANEWS) - Shares of DLTX (Oslo Børs Benchmark Index_GI: DLTX.OL) dropped by a staggering 11.46% to kr1.45 at 13:29 EST on Wednesday, after five sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI is dropping 2.97% to kr1,169.59, after five sequential sessions in a row of losses. This seems, as yet, an all-around negative trend trading session today.

About DLTX

DLT ASA, a technology company, invests in distributed ledger technology and blockchain sectors. It engages in the provision of commercial business, physical infrastructure, and software services. The company is based in Oslo, Norway.

Volume

Today's last reported volume for DLTX is 864034 which is 66.14% above its average volume of 520062.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DLTX's stock is considered to be overbought (>=80).

More news about DLTX (DLTX.OL).

Categories

stockMarket

Tags

Stock PricePrice DownMarket Session NowDLTXStock Price DownStock Market NowMarket SessionStock MarketDLTX.OLStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com